Novo Nordisk: EU endorses label update for Saxenda.
(CercleFinance.com) - Novo Nordisk said today that EMA's Committee for Medicinal Products for Human Use (CHMP) has endorsed a label update for its anti-obesity drug Saxenda.
This update is based on the results from a clinical trial which showed that Victoza, another Novo Nordisk drug, significantly reduced the risk of cardiovascular death, heart attack and non-fatal stroke by 13% versus placebo.
The CHMP has concluded that, although Saxenda was not investigated in the trial, the results would be supportive for the assessment of the drug for any potential cardiovascular risk.
Copyright (c) 2017 CercleFinance.com. All rights reserved.
This update is based on the results from a clinical trial which showed that Victoza, another Novo Nordisk drug, significantly reduced the risk of cardiovascular death, heart attack and non-fatal stroke by 13% versus placebo.
The CHMP has concluded that, although Saxenda was not investigated in the trial, the results would be supportive for the assessment of the drug for any potential cardiovascular risk.
Copyright (c) 2017 CercleFinance.com. All rights reserved.